{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancies&page=8", "query": { "condition": "Advanced Solid Tumor Malignancies", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 3365, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancies&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+Malignancies&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T12:28:42.625Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06311578", "title": "A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "JNJ-87704916", "type": "DRUG" }, { "name": "Cetrelimab", "type": "DRUG" }, { "name": "Standard of Care PD(L)-1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Enterprise Innovation Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2024-04-10", "completion_date": "2033-02-14", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 4, "location_summary": "New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06311578" }, { "nct_id": "NCT04925284", "title": "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "SCCHN", "Pancreatic Cancer", "Esophageal SCC", "Metastatic Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Epithelial Ovarian Cancer", "Endometrial Cancer", "Tissue Factor-Expressing Solid Tumors" ], "interventions": [ { "name": "XB002", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 269, "start_date": "2021-06-07", "completion_date": "2025-03-10", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925284" }, { "nct_id": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Squamous Cell Carcinoma", "Ovarian Carcinoma", "Peritoneal Carcinoma", "Fallopian Tube Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "NM21-1480", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Numab Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2020-08-19", "completion_date": "2024-02-06", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 14, "location_summary": "Fort Collins, Colorado • Augusta, Georgia • New Orleans, Louisiana + 11 more", "locations": [ { "city": "Fort Collins", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Ypsilanti", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04442126" }, { "nct_id": "NCT03717415", "title": "A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "Rebastinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2019-01-02", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 9, "location_summary": "San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03717415" }, { "nct_id": "NCT06730750", "title": "A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986490", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-02-12", "completion_date": "2029-12-09", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06730750" }, { "nct_id": "NCT00014378", "title": "Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Chinese Herb Huanglian (Coptis chinesis)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2000-10", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2015-12-18", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014378" }, { "nct_id": "NCT03284385", "title": "Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Locally Advanced Clear Cell Renal Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-01-29", "completion_date": "2027-04-22", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 29, "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 18 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03284385" }, { "nct_id": "NCT06336148", "title": "A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ACTM-838", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actym Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-06-05", "completion_date": "2025-08-28", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 2, "location_summary": "Los Angeles, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06336148" }, { "nct_id": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "GDC-0032", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2011-03-16", "completion_date": "2021-06-25", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296555" }, { "nct_id": "NCT02323191", "title": "A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Emactuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2015-01-19", "completion_date": "2020-08-21", "has_results": false, "last_update_posted_date": "2020-08-27", "last_synced_at": "2026-10-11T12:28:42.625Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323191" } ] }